CL
CLNN.US Clene Inc.
- Market cap
- USD 56.4M
- P/E
- -
- P/B
- 7.83x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is CLNN.US undervalued?
Graham numberThe Graham number of Clene Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Clene Inc. fundamental analysis
No fundamental analysis for Clene Inc. yet.
Clene Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Clene Inc.
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company's lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients w…
Full company profileClene Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Clene Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | - | - | 0.00 | 206K | 723K | 473K | 654K | 342K | 200K | 215K |
| Gross Profit | - | - | -900K | 141K | 434K | 447K | 533K | 272K | 157K | -328K |
| Operating Income | -2.39K | -324K | -16.3M | -20.2M | -50.0M | -48.4M | -40.5M | -33.1M | -23.1M | -18.3M |
| EBITDA | -2.39K | -8.49M | -15.2M | -17.0M | -8.34M | -25.6M | -43.2M | -33.7M | -22.0M | -23.9M |
| Net Income | -2.39K | -277K | -16.2M | -19.3M | -9.74M | -29.9M | -49.5M | -39.4M | -26.2M | -23.5M |
| EPS | 0.00 | -0.09 | -4.65 | -5.51 | -3.16 | -9.18 | -9.43 | -5.67 | -2.65 | -1.60 |
| Balance Sheet | ||||||||||
| Total Assets | - | 47.2M | 14.9M | 68.2M | 63.1M | 44.5M | 52.3M | 27.3M | 18.1M | 22.2M |
| Total Liabilities | - | 42.2M | 9.99M | 67.9M | 50.5M | 41.3M | 39.0M | 36.2M | 35.7M | 37.0M |
| Shareholders' Equity | - | 5.00M | 4.89M | 341K | 12.6M | 3.24M | 13.4M | -8.86M | -17.6M | -14.8M |
| Cash & Short-term Investments | - | 744K | 8.79M | 59.3M | 50.3M | 23.3M | 35.0M | 12.2M | 5.19M | 9.89M |
| Total Debt | - | 3.22M | 2.88M | 4.32M | 24.0M | 31.8M | 32.2M | 20.8M | 21.7M | 22.6M |
| Cash Flow | ||||||||||
| Operating Cash Flow | - | -205K | -13.2M | -18.9M | -34.6M | -39.0M | -30.2M | -21.3M | -18.5M | -15.6M |
| Capital Expenditure | - | 752K | 294K | 387K | 1.33M | 5.18M | 330K | 15.0K | 39.0K | 69.3K |
| Free Cash Flow | - | -957K | -13.5M | -19.3M | -36.0M | -44.2M | -30.5M | -21.3M | -18.6M | -15.7M |
| Ratios | ||||||||||
| ROE | - | -5.5% | -330.6% | -5,653.1% | -77.3% | -924.3% | -369.7% | - | - | - |
| ROA | - | -0.6% | -108.6% | -28.2% | -15.4% | -67.2% | -94.6% | -144.1% | -144.4% | -105.9% |
| Net Profit Margin | - | - | - | -9,357.8% | -1,347.2% | -6,325.2% | -7,569.4% | -11,520.5% | -13,086.5% | -10,931.7% |
| Debt to Equity | - | 0.64x | 0.59x | 12.68x | 1.91x | 9.83x | 2.40x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Clene Inc. dividends
Clene Inc. has not paid dividends in the last 8 fiscal years.
Last stock split: 1:20 on Jul 11, 2024.
Who owns Clene Inc.
- Insiders 16.33%
- Institutions 20.21%
- Public & others 63.46%
- Shares outstanding 14.4M
- Free float 11.8M
Top funds holding CLNN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| NT Ext Equity Mkt Idx Fd - DC - NL - T2 | 62.4K | 1.81% | 0.00% | Jun 2024 |
| NT Ext Eq Mkt Indx Fd DC Lending Tier 5 | 22.5K | 0.65% | 0.00% | Jun 2024 |
| BNYM Mellon SL Market Completion UC1 | 5.57K | 0.16% | 0.00% | Jun 2024 |
| BNYM Mellon NSL Mkt Completion Fund Inst | 336.00 | 0.01% | 0.00% | Jun 2024 |
Clene Inc. company profile
- Company name
- Clene Inc.
- Ticker
- CLNN.US
- Exchange
- USA Stocks
- Listed since
- Dec 31, 2020
- Sector
- Consumer Defensive
- Industry
- Biotechnology
- Employees
- 76
- Fiscal year end
- December
- Address
- 6550 South Millrock Drive, Salt Lake City, UT, United States, 84121
- Phone
- 801 676 9695
- Website
- clene.com
About Clene Inc.
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company's lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. It develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, the company markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. Clene Inc. is headquartered in Salt Lake City, Utah.
Clene Inc. management
7- Mr. Robert Etherington MBACEO, President & Director · born 1967
- Mr. Morgan R. Brown CPA, M.B.A.Chief Financial Officer · born 1968
- Mr. Mark G. Mortenson ESQ.Chief Science Officer · born 1958
- Mr. Jerry Miraglia J.D.General Counsel & Corporate Secretary
- Ms. Mary Anne McneilHead of Human Resources
- Mr. Michael T. HotchkinChief Development Officer
- Dr. Benjamin M. Greenberg M.D., M.H.S.Head of Medical